Johnson Samuel

Mr. Johnson Samuel

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2025 in Drugs and Drug Candidates
Verified
Journal Article
Open access
PDF file
SLSujatha M. L
Sujatha M. L
MKManjunatha S. Katagi
Manjunatha S. Katagi
GBGirish S. Bolakatti
Girish S. Bolakatti
JSJohnson Samuel
Johnson Samuel
BNBelakatte P. Nandeshwarappa
Belakatte P. Nandeshwarappa
Background: The cholinergic hypothesis is an elementary approach employed for the research and drug discovery of novel anti-Alzheimer therapeutics. Method: In this context, the study focuses on synthesizing and evaluating a new series of chalcone derivatives (3a–3j) as multifunctional therapeutic agents, specifically investigating their antioxidant potential using the DPPH method with ascorbic acid as a standard. Ellman’s protocol for acetylcholinesterase inhibition assay was performed using donepezil as a standard, and computational insights were explored through molecular docking and ADME profiling. Results: Compounds 3a, 3d, 3e, 3f, and 3h exhibited excellent antioxidant activity compared to the standard. Most of the compounds exhibited moderate to good (3b, 3c, and 3h) AChE inhibitory activity. Molecular docking studies revealed conventional hydrogen bonding and π-π interactions with the enzyme’s active residues, facilitated by their electronegative groups and phenyl rings, respectively. In addition, a pharmacokinetic study was conducted using computational approach to assess druggability. The results demonstrated that compound 3b is an outstanding lead candidate with appreciable AChE inhibitory activity. Conclusions: The combined experimental and computational results of this study highlight the multifunctional nature of chalcone derivatives, suggesting their potential as promising therapeutic agents for the discovery of novel AChE inhibitors that could be employed in the management of Alzheimer’s disease and oxidative stress-related diseases.

9 February 2024 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
JSJohnson Samuel
Johnson Samuel
SGSanjay Ghosh
Sanjay Ghosh
STSaravanamuthu Thiyagarajan
Saravanamuthu Thiyagarajan
The dengue virus (DENV) infects approximately 400 million people annually worldwide causing significant morbidity and mortality. Despite advances in understanding the virus life cycle and infectivity, no specific treatment for this disease exists due to the lack of therapeutic drugs. In addition, vaccines available currently are ineffective with severe side effects. Therefore, there is an urgent need for developing therapeutics suitable for effective management of DENV infection. In this study, we adopted a drug repurposing strategy to identify new therapeutic use of existing FDA approved drug molecules to target DENV2 non-structural proteins NS3 and NS5 using computational approaches. We used Drugbank database molecules for virtual screening and multiple docking analysis against a total of four domains, the NS3 protease and helicase domains and NS5 MTase and RdRp domains. Subsequently, MD simulations and MM-PBSA analysis were performed to validate the intrinsic atomic interactions and the binding affinities. Furthermore, the internal dynamics in all four protein domains, in presence of drug molecule binding were assessed using essential dynamics and free energy landscape analyses, which were further coupled with conformational dynamics-based clustering studies and cross-correlation analysis to map the regions that exhibit these structural variations. Our comprehensive analysis identified tolcapone, cefprozil, delavirdine and indinavir as potential inhibitors of NS5 MTase, NS5 RdRp, NS3 protease and NS3 helicase functions, respectively. These high-confidence candidate molecules will be useful for developing effective anti-DENV therapy to combat dengue infection.Communicated by Ramaswamy H. Sarma.

4 April 2023 in Research Square
Verified
Preprint
Open access
PDF file
JSJohnson Samuel
Johnson Samuel
MBMadhushruti Borah
Madhushruti Borah
FCFilippo Castiglione
Filippo Castiglione
SPSharangouda J. Patil
Sharangouda J. Patil
Human Herpesvirus 3 (HHV3), commonly known as the Varicella zoster virus (VZV), is a highly infectious α-herpesvirus that causes Varicella (chicken pox) on primary infection, as well as Herpes zoster (shingles) on latent reactivation. Life-threatening sequelae and complications such as post-herpetic neuralgia (PHN), meningoencephalitis, myelopathy, skin necrosis, etc. have also been observed in some immunocompromised individuals. Although effective vaccines have been developed against VZV, they are limited by the scope of vaccination and in some cases by the vaccine efficacy. Addressing the need for a much safer and more efficient vaccine, an in-silico approach-based study was carried out to design a multi-epitope vaccine against VZV. Accounting for their crucial role in the viral entry mechanism, the envelope glycoproteins were analyzed for potent epitopes that can induce cytotoxic T cells, Helper T cells, and B cells. These epitopes were further screened using various computational tools, for constructing a multi-epitope vaccine, via the addition of suitable linkers and an adjuvant. Antigenicity, allergenicity, conservancy, population coverage, and other physiochemical properties of the final vaccine construct were evaluated, post which their structural properties and the interaction patterns with TLR1 and TLR4 were analyzed. Further, the vaccine construct was subjected to molecular dynamics simulation studies, in order to assess its structural stability. Finally, the multi-epitope vaccine was codon optimized and cloned into the expression vector pET-28a+, to have it expressed efficiently in the K12 strain of E.Coli bacteria. The immune reactions triggered by the vaccine candidate were validated using immune simulation studies. Laboratory validation of the findings for its immunogenicity and safety can help in assessing the in vivo efficiency of the vaccine to prevent VZV infection.

31 December 2025 in Drugs and Drug Candidates
Verified
Journal Article
Open access
PDF file
SLSujatha M. L
Sujatha M. L
MKManjunatha S. Katagi
Manjunatha S. Katagi
GBGirish S. Bolakatti
Girish S. Bolakatti
JSJohnson Samuel
Johnson Samuel
BNBelakatte P. Nandeshwarappa
Belakatte P. Nandeshwarappa
The journal retracts the article titled “Exploring Chalcone Derivatives as a Multifunctional Therapeutic Agent: Investigating Antioxidant Potential, Acetylcholinesterase Inhibition and Computational Insights”